Clinical trials: Viral Pneumonia
- Condition Viral Pneumonia
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
SARS-CoV2 Infection
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
- Trial name
- NCT04323761
- Testing
- Remdesivir
- Where
- 272 sites in United States, Australia and 25 more
- Sponsor
- Gilead Sciences
Covid19
Canine COVID-19 Detection
Dogs are some of nature's greatest detectives, owing to their incredible sense of smell and ability to be trained. Most of us will be familiar with seeing trained sniffer dogs at airports looking for drugs and other prohibited…
- Trial name
- NCT04509713
- Testing
- Collection of odour samples
- Where
- United Kingdom
- Volunteers
- 16,250 people, healthy volunteers welcome
- Sponsor
- ARCTEC
Coronavirus Disease-2019 (COVID-19) Prevention
A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive
The primary purpose of this study is to assess the safety, reactogenicity, and humoral immune response of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule or as a 2-dose schedule (56-day interval) in adolescents.
- Trial name
- HORIZON 2 (NCT05007080)
- Testing
- Ad26.COV2.S
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination…
- Trial name
- NCT05193279
- Testing
- Candidate vaccine, SCB-2019
- Where
- 2 sites in Colombia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Pneumonia, Pneumocystis Carinii, HIV Infections
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole
To compare the safety of atovaquone (566C80) with intravenous (IV) pentamidine for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients who are intolerant of therapy with trimethoprim /…
- Trial name
- NCT00001996
- Testing
- Atovaquone, Pentamidine isethionate
- Where
- 20 sites in United States
- Sponsor
- Glaxo Wellcome
Sars-CoV-2 Infection, COVID-19
COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
SARS-CoV-2 rapid antigen over the counter usability study.
- Trial name
- NCT05584189
- Testing
- Rapid SARS-CoV-2 Antigen Test
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- MP Biomedicals, LLC
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid 19
GlowTest COVID-19 Antigen Home Test Kit QRI Use Study
The objective of the study is to determine the usability of the GlowTest COVID-19 Antigen Home Test in a simulated home use environment.
- Trial name
- NCT05140005
- Testing
- GlowTest COVID-19 Antigen Home Test
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Arion Bio
COVID-19
A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19
phase I study will evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 3 years and older.
- Trial name
- NCT04869592
- Testing
- low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell), high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
- Where
- China
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Pneumonia, Pneumonia in Children
Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia
The main questions this study aims to answer are: Does using probiotic nasal spray (LiveSpo Navax containing Bacillus subtilis and Bacillus clausii, 1x10^9 CFU/mL), with or without oral probiotics (LiveSpo Pregmom containing…
- Trial name
- NCT07399717
- Testing
- Navax, Navax-PregMom
- Where
- Vietnam
- Volunteers
- 330 people
- Sponsor
- Anabio R&D
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR-VA (NCT05663957)
- Testing
- Evusheld
- Where
- United States
- Volunteers
- 5,814 people
- Sponsor
- AstraZeneca
COVID-19, Influenza A
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the…
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT05354115
- Testing
- Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
- Where
- United States
- Volunteers
- 676 people
- Sponsor
- Abbott Rapid Dx
COVID-19, Coronavirus
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.
- Conditions
- COVID-19, Coronavirus, Mortality
- Trial name
- IDENTIFY (NCT04423991)
- Testing
- COViage
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Dascena
SARS-CoV-2 Infection, COVID-19
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
This is a Phase 3, randomized, observer-blind study in healthy individuals. The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2): As a 30-microgram dose…
- Trial name
- NCT04713553
- Testing
- BNT162b2, BNT162b2.B.1.351
- Where
- 17 sites in United States
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
This study is a phase Ⅱ clinical trial to evaluate the safety and immunogenicity of SCTV01E-2 in people of different ages who had been vaccinated with COVID-19 vaccines.
- Trial name
- NCT05933512
- Testing
- SCTV01E-2, SCTV01E
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Serological and PCR Testing for COVID-19
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results.
- Trial name
- NCT04404062
- Testing
- Membrane-based immunoassay kit, Quantitative antibody Tests, PCR Test
- Where
- United Kingdom
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
COVID-19
Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective for treatment of mild COVID-19 illness. Adults and adolescent participants will be followed for approximately 28 days.
- Trial name
- NCT05157269
- Testing
- Nitazoxanide, Vitamin Super-B Complex
- Sponsor
- Romark Laboratories L.C.
COVID-19
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney…
- Trial name
- REDPINE (NCT04745351)
- Testing
- Remdesivir, Standard of Care
- Where
- 63 sites in United States, Brazil and 4 more
- Volunteers
- 249 people
- Sponsor
- Gilead Sciences
Pneumonia, Pneumocystis Carinii, HIV Infections
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.
To provide trimetrexate glucuronate to immunosuppressed patients with Pneumocystis carinii pneumonia (PCP) for whom this investigational compound could provide significant medical benefit.
- Trial name
- NCT00002102
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Sponsor
- U.S. Bioscience
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Neutrexin Plus Leucovorin in the Treatment of Pneumocystis Carinii Pneumonia (PCP)
To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to…
- Trial name
- NCT00002434
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Sponsor
- U.S. Bioscience